Cellebrite DI (NASDAQ:CLBT) Cut to Sell at Wall Street Zen

Wall Street Zen downgraded shares of Cellebrite DI (NASDAQ:CLBT) from a hold rating to a sell rating in a research note released on Saturday morning.

Other equities research analysts have also issued research reports about the company. Lake Street Capital raised their price objective on Cellebrite DI from $22.00 to $23.00 and gave the company a “buy” rating in a research note on Thursday, November 13th. JPMorgan Chase & Co. upped their target price on Cellebrite DI from $23.00 to $24.00 and gave the company an “overweight” rating in a research report on Thursday, November 13th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Cellebrite DI in a research note on Monday, December 29th. Bank of America raised their price target on shares of Cellebrite DI from $24.00 to $25.00 and gave the stock a “buy” rating in a research report on Thursday, November 13th. Finally, Needham & Company LLC cut their price target on shares of Cellebrite DI from $24.00 to $18.00 and set a “buy” rating on the stock in a report on Thursday, February 12th. Four research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $22.50.

Cellebrite DI Price Performance

Shares of CLBT stock opened at $14.93 on Friday. The company’s fifty day moving average price is $15.54 and its two-hundred day moving average price is $16.95. The firm has a market capitalization of $3.72 billion, a P/E ratio of 48.16, a P/E/G ratio of 2.35 and a beta of 1.30. Cellebrite DI has a 12 month low of $11.76 and a 12 month high of $20.86.

Cellebrite DI (NASDAQ:CLBT) last announced its earnings results on Wednesday, February 11th. The company reported $0.14 earnings per share for the quarter, meeting the consensus estimate of $0.14. Cellebrite DI had a return on equity of 20.43% and a net margin of 16.47%.The company had revenue of $128.82 million during the quarter, compared to the consensus estimate of $126.07 million. During the same period last year, the firm earned $0.10 earnings per share. The company’s revenue was up 28.8% on a year-over-year basis. On average, sell-side analysts anticipate that Cellebrite DI will post 0.3 EPS for the current year.

Institutional Inflows and Outflows

A number of large investors have recently bought and sold shares of CLBT. Financial Management Professionals Inc. bought a new stake in shares of Cellebrite DI in the 3rd quarter valued at approximately $28,000. CWM LLC lifted its stake in Cellebrite DI by 85.7% during the third quarter. CWM LLC now owns 1,560 shares of the company’s stock worth $29,000 after purchasing an additional 720 shares during the last quarter. Towarzystwo Funduszy Inwestycyjnych PZU SA lifted its stake in Cellebrite DI by 81.0% during the fourth quarter. Towarzystwo Funduszy Inwestycyjnych PZU SA now owns 1,900 shares of the company’s stock worth $34,000 after purchasing an additional 850 shares during the last quarter. Toth Financial Advisory Corp acquired a new position in Cellebrite DI in the third quarter worth $38,000. Finally, PNC Financial Services Group Inc. boosted its holdings in Cellebrite DI by 1,998.0% in the second quarter. PNC Financial Services Group Inc. now owns 2,098 shares of the company’s stock worth $34,000 after purchasing an additional 1,998 shares during the period. Institutional investors own 45.88% of the company’s stock.

Cellebrite DI Company Profile

Cellebrite DI is a global provider of digital intelligence and forensics solutions that enable law enforcement agencies, government bodies and enterprises to extract, analyze and act on data from mobile devices, cloud services and digital sources. The company’s technology is designed to accelerate investigations, support evidence-based decision-making and enhance security operations by delivering actionable intelligence in a secure, scalable platform.

The company’s flagship offerings include the Universal Forensic Extraction Device (UFED) series for data acquisition and decoding, Physical Analyzer for advanced data parsing and visualization, and Pathfinder for case-driven investigation workflows.